Kornimate/medical-research-clean huggingface dataset:
comparison of dry needling and manual pressure release for managing low back pain

Conditions: Low Back Pain

Summary: this study will compare the effect of dry needling and manual pressure in patients having low back pain in terms of pain and disability. there will be two groups ; experimental and control. half of study group will receive dry needling session along with hot pack. half of study group will receive manual pressure technique along with hot pack.

the study is randomized control trail , which is being conducted in fauji foundation hospital and foundation university college of rehabilitation (oct 2022-feb 2023) . sample size of 50 individual was calculated using epitool with 95% confidence interval (ci), and power 80%. sample will be collected through pilot study . both groups will recieve conventional physiotherapy protocol (hot pack) assessment will be done on baseline, and 4th week .

Eligibility criteria:
inclusion criteria:- * age between 30-60 * pateint with subacute and chronic low back pain at least last 6 months. * pateint with active mtrps. exclusion criteria: * patient with fibromyalgia * pregnant females * patient with chronic diseases (osteoporosis, lungs disease and diabetes) * patient with musculoskeletal injuries * patient that are using any medication to relief pain like analgesic or muscle relaxants * any treatment for back pain in same period of research. * patient having any radiculopathies or discogenic low back pain
regional analgesia at the pediatric emergency department

Conditions: Regional Anaesthesia

Summary: approximately two years ago, ultrasound-guided regional blocks technique was introduced into routine use in the pediatric emergency department at hillel yaffe medical center. since then, nearly 300 different blocks have been performed. study objective: to collect a registry database of complication rates associated with regional analgesia during routine pediatric emergency department care between 2023 and 2025.

adequate pain management is a key component of pediatric emergency care. the use of regional analgesia, particularly ultrasound-guided regional blocks, has gained momentum in recent years as part of pain management, reducing the need for opioids and serving as a safe and effective alternative to procedural sedation. for anesthesiologists, this is now a routine tool mainly performed in the operating room. in adult emergency medicine, this tool has also been integrated and is sometimes performed by emergency physicians. in children, performing ultrasound-guided regional blocks presents additional challenges compared to adults. the primary challenge in an unsedated child is maintaining cooperation throughout the procedure. other difficulties include limited maneuverability due to their smaller size, reduced allowable volume of local anesthetics (based on weight), and more. for these reasons, most ultrasound-guided regional blocks in children are performed in the operationg room after sedation or general anesthesia. there are only a few case reports describing the use of simple ultrasound-guided regional blocks performed by emergency physicians in pediatric ed settings. approximately two years ago, this technique was introduced into routine use in the pediatric emergency department at hillel yaffe medical center. since then, nearly 300 different blocks have been performed. study objective: to collect a registry database of complication rates associated with regional analgesia during routine pediatric emergency department care between 2023 and 2025.

Eligibility criteria:
inclusion criteria: * children who visited the pediatric emergency department between 2023-2025 and underwent a nerve block during their visit. exclusion criteria: * children who visited the emergency department but had the nerve block performed outside the emargency department setting (e.g., inpatient wards or operationg room), or if the block was performed by a physician not affiliated with the pediatric emergency department.
eye movement tracking to detect impairment due to acute cannabis intoxication

Conditions: Impairment; Cannabis Intoxication

Summary: the purpose of this study is to determine the accuracy of an impairment algorithm based on eye tracking while watching a short film clip, in comparison to a clinical reference standard of impairment.


Eligibility criteria:
inclusion criteria: 1. provide written informed consent. 2. have the ability to provide a complete ophthalmologic, medical and neurologic history as well as report medications/drugs/alcohol consumed within the 24 hours prior to tracking. 3. be at least 18 years old. exclusion criteria: 1. be blind (no light perception), have missing or non-functional eyes. 2. be unable to open their eyes. 3. have a history of unresolved strabismus, diplopia, amblyopia. 4. have a history of unresolved cranial nerve iii, iv, or vi palsy. 5. have a history of unresolved macular edema, retinal degeneration, extensive cataract, or ocular globe disruption. 6. have a history of extensive prior eye surgery (examples include strabismus surgery, scleral buckle repair of retinal detachment, repair of blow out fractures of the orbit and any procedures that would interfere with extraocular muscle movements; prior cataract surgery or lasik are not exclusions) or scarring. 7. have a prior history of unresolved ocular-motor dysfunctions. 8. have used cannabis, alcohol etc. 24 hours before study commences. 9. be 100% naïve to cannabis usage. 10. be pregnant.
health effects of wood smoke and traffic-related air pollution exposures: a necessary comparison

Conditions: Healthy Individuals; Allergic Rhinitis

Summary: accumulating evidence demonstrates that breathing air pollutants leads to devastating increases in sickness and death worldwide over time. however, there is little data comparing the effects of different types of air pollution on health. in canada, traffic-related air pollution and wood smoke (wildfires and wood burning for heating) are very common air pollutants. this study aims to safely complete a controlled human exposure study to test how these air pollution types acutely affect health.

healthy adult participants (total 48; 24 of each biological sex assigned at birth) will breathe filtered air (control), wood smoke (ws), diesel exhaust (de), and de plus ws (dews) each for 2 hours, with 4 weeks between each exposure (washout). before and after each exposure, participants will answer questions, perform breathing tests, and give blood samples. at 24 hours after each exposure, participants will undergo a bronchoscopy to collect samples from their lungs. the study will look at what (if any) are the differences between breathing in fresh air (filtered air - fa) or polluted air containing either wood smoke (ws), diesel exhaust (de) or diesel exhaust plus wood smoke (dews). the research team will use wood smoke generated from pine wood, since it is one of the most common types of wood found in western canadian forests where forest fires occur. the investigators will evaluate multiple endpoints as detailed in the outcome measures section. for each applicable endpoint, the investigators will evaluate stratified analyses and effect modification by biological sex, participant age, gene score, and microbiomes.

Eligibility criteria:
inclusion criteria: * age 19-40 * healthy, with no history of respiratory disease * lifetime non-smoker and non-vaper. exclusion criteria: * pregnant, planning to become pregnant, or breastfeeding during the study period (confirmed through pregnancy tests at each visit if applicable) * frequent ws or de exposures (e.g. home fireplace used for heating/cooking, or employment in transportation, mining, or as a firefighter).

Keywords: air pollution wood smoke diesel exhaust
use of kudzu extract in the study of its ability to reduce alcohol drinking in treatment seeking alcohol dependent persons

Conditions: Alcohol Abuse; Alcohol Dependence; Heavy Drinking Days

Summary: this research is designed to assess if problem drinking by treatment seeking individuals can be treated (reduced) by kudzu extract pharmacotherapy plus medical management therapy.

men and women participants, ages 21-60 yrs old and seeking treatment for their drinking, but otherwise physically and mentally healthy, will be recruited. participants must meet criteria for heavy drinking\* and either alcohol abuse or alcohol dependence according to dsm-iv criteria. following a baseline period, participants will be randomized to take either kudzu extract or placebo for 10 weeks, and record and report their alcohol consumption. all participants will receive weekly medical management sessions with the study physician. \*heavy drinking according to the national institute on alcohol abuse and alcoholism (2007) is more than 4 drinks per day and more than 14 drinks per week for men; and for women, more than 3 drinks per day and more than 7 drinks per week.

Eligibility criteria:
inclusion criteria: * treatment seeking for alcohol abuse or dependence. * non cigarette smokers are preferred, but will accept those who smoke less than 10 cigarettes per day. * marijuana use of less than once per week. other drug use less than 20 lifetime uses. * absence of current axis i disorders except alcohol abuse or dependence. past diagnosis (greater than 1 year) is acceptable. * bmi within 18-30. * physically healthy (normal physical exam, ecg, blood and urine chemistries). * female participants must use medically approved method of contraception. if barrier method is used, must agree to using two methods simultaneously (e.g., diaphragm and condom). exclusion criteria: * taking any prescription medication (except oral contraceptives, certain short term anti -fungal agents and some topical creams for dermal conditions). * on psychotropic medications. * drug use (other than nicotine, alcohol or marijuana) greater than 20 lifetime uses. * meets criteria for current drug abuse or dependence (other than alcohol and nicotine). past abuse/dependence (greater than 3 years) is acceptable. * history of major head trauma. * history of cardiac problems. * pregnancy, lactating, or planning to become pregnant during the study period.

Keywords: alcohol abuse alcohol dependence heavy drinking days kudzu
intra-uterine injection of human chorionic gonadotrophin (hcg) before embryo transfer

Conditions: Infertility

Summary: chorionic gonadotrophins (hcg) play an important role in implantation. the aim of the study is to evaluate the effect of intrauterine injection of hcg before embryo transfer in ivf/icsi on the implantation and pregnancy rates. the rational is that intrauterine hcg injection will attract regulatory t cells and improve implantation.

background : human chorionic gonadotrophin ( hcg) was found to secreted immediately after fertilization by the embryo. it plays an important role in implantation and in attracting regulatory t cells to the endometrium. rational : intrauterine injection of hcg before embryo transfer in ivf/icsi may increase endometrial regulatory t cells ( treg ) and improve the implantation and pregnancy rates. aim of the work : to study the effect of intrauterine injection of hcg before embryo transfer on the implantation and pregnancy rates after ivf/icsi. subjects : infertile patients undergoing icsi. inclusion criteria : * female age less than 40 years * male factor infertility * normal female hormonal profile and uterine cavity exclusion criteria : * previous icsi failure * azoospermia * endometriosis study group: intrauterine injection of 100 iu of hcg (group 1)or 200 iu of hcg ( group 2) will be done during the dummy embryo transfer which is done 10-15 minutes before the actual embryo transfer. control group: the embryo transfer will be done without prior intrauterine injection of hcg main outcome measures : implantation and pregnancy rates secondary outcome measures : miscarriage and delivery rates

Eligibility criteria:
inclusion criteria: * male factor infertility * normal female hormonal profile * normal uterine cavity exclusion criteria: * previous icsi failure * endometriosis * azoospermia

Keywords: hcg pregnancy implantation icsi ivf
electronic cigarette-derived oxidants and cardiopulmonary effects

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this is a pilot study on the impact of switching from cigarettes to electronic cigarettes (ec) on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting chronic obstructive pulmonary disease (copd). the researchers hypothesize that the smokers who switch to ec completely or significantly will experience reduced copd symptoms, risks of exacerbations, and decreased levels of oxidative stress and inflammation.

smokers with copd have a higher pack-year history and nicotine dependence compared to regular smokers as exemplified by the relatively large proportion of patients diagnosed with copd that continue to smoke (95%). this is a translational project which addresses the changing profile of tobacco product use in the united states (us) and the need for data regarding toxicity pathways for new nicotine products such as ec. in particular it focuses on critical scientific and clinically relevant gaps relating to oxidants in ec and their potential long-term cardiopulmonary effects. the study will obtain new information regarding the potential cardiopulmonary toxicity resulting from exposure to ec-derived oxidants that may lead to long-term disease development.

Eligibility criteria:
inclusion criteria: * mild to moderate copd * smokes a popular brand of cigarette * willing to use an e-cigarette to reduce cigarette smoking down to 75% of their daily baseline cigarette use * ability to read, write and understand english * ability to provide informed consent and attend study visits exclusion criteria: * history of active, chronic drug abuse or alcohol abuse problems * actively changing smoking behavior * unwilling or unable to provide blood samples * pregnant, planning to become pregnant, or nursing * use of tobacco products other than cigarettes in the past 30 days * recent history (\< 6 months) of myocardial infarction (mi) * any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or drug therapy within the past year. antiarrhythmic drugs include amiodarone, flecainide, iv ibutilide, iv lidocaine, procainamide, propafenone, quinidine, tocainide * hospitalization for heart failure (ny heart association iii or iv) within the past year * uncontrolled hypertension * known allergy to vegetable glycerin and propylene glycol * history of seizures or medications to prevent seizures
study to evaluate amg 162 in the prevention of postmenopausal osteoporosis

Conditions: Postmenopausal Osteoporosis

Summary: this study will determine whether treatment with amg 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of amg 162 in this population.


Eligibility criteria:
eligibility criteria - postmenopausal women with osteopenia (lumbar spine bone mineral density t-score between 1.0 and -2.5)

Keywords: osteoporosis postmenopausal
do emotions affect mechanical pain thresholds in individuals with chronic pain?

Conditions: PRESSURE PAIN THRESHOLD

Summary: the purpose of this study is to investigate if different emotional states could influence mechanical pain thresholds in individuals with chronic pain.

participants will be randomized into 4 different groups watching different short video-clips (2.20 min). the negative emotions group will watch an uncomfortable short video containing violence and blood, the positive emotions group will watch a video containing a stand-up comedy show, the neutral emotions group will watch a video about how to paint a house, and the control group will just wait for 2.20 min, without any instructions about what to think about. pressure pain thresholds will be measured with an algometer before and after the video-clips.

Eligibility criteria:
inclusion criteria * above 18 years of age * fluent in swedish * persistent chronic pain with duration \> 6 months exclusion criteria * known neurological disease

Keywords: pressure pain threshold pain emotion
combination chemotherapy in treating patients with recurrent or advanced cancer of the uterus

Conditions: Sarcoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin in treating patients with recurrent or advanced cancer of the uterus.

objectives: i. estimate the antitumor activity of the combination of mitomycin, doxorubicin, and cisplatin (map) in patients with recurrent or advanced uterine sarcomas. ii. determine the nature and degree of toxicity of map chemotherapy in this cohort of patients. outline: patients receive iv doxorubicin, mitomycin, and cisplatin over 3 hours once every 3 weeks, for a minimum of 1 course. patients who have complete response, partial response, or stable disease will continue for at least 3 courses. if side effects are not severe, patients may remain on the study regimen at the investigator's discretion for a maximum of 6 courses. all patients are followed until death. projected accrual: the first stage of accrual is anticipated to accrue 20 evaluable patients in approximately 12 months. if indicated, a second stage will accrue approximately 10 evaluable patients.

Eligibility criteria:
disease characteristics: histologically confirmed advanced, persistent, or recurrent uterine sarcoma documented disease progression after local therapy measurable disease consisting of abdominal, pelvic, chest, or other masses that can be defined in at least two dimensions by palpation, x-ray, computed tomography or ultrasound patient characteristics: age: no age specified performance status: karnofsky 50%-100% life expectancy: not specified hematopoietic: wbc at least 3,000/mm3 granulocyte count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 times normal sgot no greater than 3 times normal alkaline phosphatase no greater than 3 times normal renal: creatinine no greater than 1.5 times normal cardiovascular: ejection fraction within institutional normal limits pulmonary: not specified other: no active infection no concurrent second malignancy other than nonmelanoma skin cancer must be disease free of any prior malignancy for at least 5 years and not received any treatments with chemotherapy or radiation therapy for that malignancy prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy endocrine therapy: not specified radiotherapy: at least 6 weeks since radiotherapy recovered from effects of radiotherapy surgery: recovered from effects of surgery

Keywords: stage iii uterine sarcoma stage iv uterine sarcoma recurrent uterine sarcoma
current treatment strategy of patients with multivessel disease or left main coronary artery disease indicated for coronary artery bypass graft surgery

Conditions: Coronary Artery Disease

Summary: according to 2011 accf/aha guideline and 2014 esc/eacts guideline, cabg surgery was recommended for three-vessel coronary artery disease and left main coronary artery disease in the patients with stable ischemic heart disease as class i. 2-vd with proximal left anterior descending artery stenosis was also indicated for cabg surgery as class i recommendation. however, many patients have been recommended for pci by catheterization laboratory cardiologist; 46% and 93% in the only-cabg candidates and both cabg and pci candidates, retrospectively, defined by previous acc/aha guideline. although the discordance between real practice in catheterization laboratory and guideline would be adjusted by recently updated guideline. the revascularization strategy for patients with 3-vd/lmd in real practice have been getting toward more pci and less cabg surgery. in this study, we will identify the rate of cabg candidates who were treated with pci or medical treatment instead of cabg surgery in different from current guideline. we are also going to compare two treatment strategies cabg surgery vs. pci with 2nd generation des regarding clinical outcomes.


Eligibility criteria:
inclusion criteria: * patients ≥ 19 years old * left main disease, three-vessel disease or two-vessel disease with proximal lad stenosis. exclusion criteria: * previous pci within 1 year * previous sternotomy * primary pci for stemi * contraindication or hypersensitivity to anti-platelet medications or contrast media * planned need for concomitant other cardiac surgery (eg, valve surgery or resection of aortic or left ventricular aneurysm, etc) * pregnant women or women with potential childbearing * inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator * inability to understand or read the informed content
a double-blind, comparative, randomized clinical study of the pharmacokinetics, safety, and immunogenicity of a single intravenous infusion of bcd-178 or perjeta® in healthy volunteers

Conditions: Breast Cancer

Summary: this is a double-blind, comparative, randomized phase i study comparing pharmacokinetics, safety and immunogenicity profiles of a biosimilar pertuzumab (bcd-178) and perjeta after a single intravenous infusion in healthy male volunteers


Eligibility criteria:
inclusion criteria: * signed informed consent; * men aged 18-45 years; * body mass index (bmi) in the range of 18.5 30.0 kg/m2; * the confirmed "healthy" status; * left ventricular ejection fraction (lvef) \> 50 % based on the results of echocg at screening; * willingness of the volunteers and their sexual partners of childbearing potential to use reliable methods of contraception, starting from signing the informed consent form, during the study, and for 6 months after the drug administration; exclusion criteria: * known allergy or intolerance to monoclonal antibody products (murine, chimeric, humanized, fully human) or any other components of the study drugs; * values of standard laboratory and instrumental parameters exceeding the normal limits accepted at the study site; * history or evidence of any chronic disease